Credit Suisse Group reaffirmed their neutral rating on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a research report report published on Wednesday morning, Briefing.com Automated Import reports.
ALDR has been the topic of several other research reports. Cantor Fitzgerald restated a buy rating and issued a $25.00 price target on shares of Menlo Therapeutics in a research note on Thursday, May 2nd. Canaccord Genuity upgraded Fortuna Silver Mines from a hold rating to a buy rating in a research note on Thursday, March 14th. They noted that the move was a valuation call. Mizuho set a $100.00 price target on PRA Health Sciences and gave the stock a hold rating in a research note on Friday, May 3rd. Cowen set a $150.00 price target on Tesla and gave the stock a sell rating in a research note on Friday, May 3rd. Finally, Zacks Investment Research upgraded HB Fuller from a sell rating to a hold rating in a research note on Wednesday, July 3rd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the company. Alder Biopharmaceuticals presently has a consensus rating of Buy and a consensus target price of $19.82.
Shares of NASDAQ:ALDR opened at $11.45 on Wednesday. Alder Biopharmaceuticals has a 52-week low of $9.44 and a 52-week high of $20.87. The stock has a 50 day moving average price of $11.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 8.34 and a quick ratio of 8.34.
In other Alder Biopharmaceuticals news, EVP James B. Bucher sold 1,897 shares of the stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $13.85, for a total transaction of $26,273.45. Following the sale, the executive vice president now directly owns 11,706 shares in the company, valued at approximately $162,128.10. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 15.40% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc boosted its stake in Alder Biopharmaceuticals by 7.3% during the 4th quarter. Legal & General Group Plc now owns 24,842 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 1,698 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in Alder Biopharmaceuticals by 22.2% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 24,200 shares of the biopharmaceutical company’s stock valued at $432,000 after purchasing an additional 4,400 shares during the last quarter. LPL Financial LLC boosted its stake in Alder Biopharmaceuticals by 43.4% during the 4th quarter. LPL Financial LLC now owns 18,175 shares of the biopharmaceutical company’s stock valued at $186,000 after purchasing an additional 5,500 shares during the last quarter. TD Asset Management Inc. boosted its stake in Alder Biopharmaceuticals by 4.2% during the 1st quarter. TD Asset Management Inc. now owns 220,064 shares of the biopharmaceutical company’s stock valued at $3,004,000 after purchasing an additional 8,881 shares during the last quarter. Finally, Empire Life Investments Inc. purchased a new stake in Alder Biopharmaceuticals during the 1st quarter valued at $130,000.
About Alder Biopharmaceuticals
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.